<DOC>
	<DOCNO>NCT01225666</DOCNO>
	<brief_summary>This study aim assess safety , tolerability Pharmacokinetics/ Pharmacodynamics ( PK/PD ) profile three dos MOD-4023 weekly regime one dose every-other-week regime administer period 4 week Growth Hormone Deficient Adult ( GHDA ) patient previously stable r-hGH treatment . An additional extension period 16 week once-weekly administration MOD-4023 aim confirm dose selection future trial .</brief_summary>
	<brief_title>MOD-4023 ( Long-Lasting Human Growth Hormone ( hGH ) ) Study Growth Hormone Deficient Adults ( GHDA )</brief_title>
	<detailed_description>The study phase II , randomize , open-label , parallel , 4 active treatment arm study evaluate safety , tolerability PK/PD profile MOD-4023 pre-treated , normalized , GHD adult . The study conduct 2 stage . Stage I 4-week treatment period 4 different dose levels/dosing regimen . Stage II 16-week treatment-extension period patient start dose ( derived stage I ) dose titrate maintain IGF-1 level within normal range .</detailed_description>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Genders Eligible Study : Both Ages Eligible Study : Males 23 60 year , Females 23 50 year . GHDA subject define Consensus guideline diagnosis treatment adult GH deficiency II ( 2007 ) . Patients use hormonal replacement therapy ( ) deficiencies hypothalamopituitary ax must optimize stable treatment regimen ( hormone level within normal range screen ) least three month prior screen : Temporary adjustment glucocorticoid replacement therapy , appropriate , acceptable . Peripheral thyroid hormone ( FT4 , FT3 ) within normal range . Fertile females must agree use appropriate contraceptive method Female patient must negative serum pregnancy test inclusion . Growth Hormone ( GH ) replacement therapy 6 month register GH product . The IGFI level screen within 1.5 +1.5 SDS age sex normal range accord central laboratory measurement . Body Mass Index ( BMI , kg/m2 ) 22.0 35.0 kg/m2 , inclusive Confirmed negative anti rhGH antibody time screen . Willing able provide write informed consent prior perform study procedure . Females pregnant breastfeed Evidence growth pituitary adenoma intracranial tumor within last 12 month ( confirm computer tomography ( CT ) magnetic resonance imaging ( MRI ) scan ( contrast ) within 3 month prior study entry screening ) . History malignancy ) cranial irradiation ( cranial tumor leukemia ) cause GHD ii ) fully treat basal cell carcinoma Signs intracranial hypertension screen Heart insufficiency , NYHA class great 2 History impair glucose tolerance , insulin resistance overt diabetes mellitus define accord American Diabetes Association ( ADA ) Criteria Impaired liver function define elevation liver enzymes &gt; 2 x upper limit normal Impaired kidney function define increase serum creatinine level &gt; 1.5 x upper limit normal Active acromegaly last 18 month le 6 month active r hGH replacement therapy Active Carpal tunnel syndrome PraderWilli syndrome Active Cushing 's syndrome within last 12 month Systemic corticosteroid replacement dos within 3 month study entry ( temporary adjustment glucocorticoid , appropriate , acceptable ) Anabolic steroid gonadal steroid replacement therapy within 2 month study entry History noncompliance medication , uncooperativeness drug abuse Blood donation major blood loss &gt; 500 mL within past 90 day prior study entry Patients , base investigator 's judgment , clinically significant unstable medical surgical condition may preclude safe complete study participation . Conditions may include cardiovascular , peripheral vascular , pulmonary , hepatic , renal , neurological disease , determine medical history , physical examination , laboratory test ECG Patients participate investigational medicinal product ( IMP ) study within last 2 month History positive serology HBC , HBV HIV</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>MOD-4023</keyword>
	<keyword>Growth Hormone Deficient Adults</keyword>
	<keyword>Phase II</keyword>
</DOC>